As of 2024-07-27, the EV/EBITDA ratio of Myriad Genetics Inc (MYGN) is -43.42. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MYGN's latest enterprise value is 2,444.40 mil USD. MYGN's TTM EBITDA according to its financial statements is -56.30 mil USD. Dividing these 2 quantities gives us the above MYGN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.7x - 14.3x | 12.8x |
| Forward P/E multiples | 11.4x - 19.2x | 14.2x |
| Fair Price | (6.45) - (8.24) | (7.79) |
| Upside | -123.3% - -129.8% | -128.2% |
| Date | EV/EBITDA |
| 2024-07-26 | -43.42 |
| 2024-07-25 | -43.74 |
| 2024-07-24 | -44.01 |
| 2024-07-23 | -44.00 |
| 2024-07-22 | -43.58 |
| 2024-07-19 | -40.72 |
| 2024-07-18 | -41.75 |
| 2024-07-17 | -42.52 |
| 2024-07-16 | -43.00 |
| 2024-07-15 | -41.79 |
| 2024-07-12 | -41.44 |
| 2024-07-11 | -40.60 |
| 2024-07-10 | -39.38 |
| 2024-07-09 | -39.54 |
| 2024-07-08 | -39.58 |
| 2024-07-05 | -39.00 |
| 2024-07-03 | -39.08 |
| 2024-07-02 | -38.77 |
| 2024-07-01 | -37.50 |
| 2024-06-28 | -38.29 |
| 2024-06-27 | -38.05 |
| 2024-06-26 | -38.55 |
| 2024-06-25 | -38.61 |
| 2024-06-24 | -38.39 |
| 2024-06-21 | -37.97 |
| 2024-06-20 | -37.23 |
| 2024-06-18 | -37.39 |
| 2024-06-17 | -37.60 |
| 2024-06-14 | -36.26 |
| 2024-06-13 | -36.41 |
| 2024-06-12 | -36.84 |
| 2024-06-11 | -35.09 |
| 2024-06-10 | -34.64 |
| 2024-06-07 | -34.56 |
| 2024-06-06 | -34.82 |
| 2024-06-05 | -35.46 |
| 2024-06-04 | -34.88 |
| 2024-06-03 | -34.90 |
| 2024-05-31 | -35.56 |
| 2024-05-30 | -35.07 |
| 2024-05-29 | -35.46 |
| 2024-05-28 | -36.46 |
| 2024-05-24 | -36.20 |
| 2024-05-23 | -36.38 |
| 2024-05-22 | -37.53 |
| 2024-05-21 | -38.16 |
| 2024-05-20 | -39.17 |
| 2024-05-17 | -39.62 |
| 2024-05-16 | -38.53 |
| 2024-05-15 | -38.61 |